STOCK TITAN

Avadel Pharmaceuticals plc - AVDL STOCK NEWS

Welcome to our dedicated news page for Avadel Pharmaceuticals plc (Ticker: AVDL), a resource for investors and traders seeking the latest updates and insights on Avadel Pharmaceuticals plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Avadel Pharmaceuticals plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Avadel Pharmaceuticals plc's position in the market.

Rhea-AI Summary
Avadel Pharmaceuticals plc (AVDL) to participate in the 23rd Annual Needham Healthcare Conference with a fireside chat on April 8th. The event will be live webcasted and archived for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
conferences
-
Rhea-AI Summary
Avadel Pharmaceuticals plc (AVDL) will participate in upcoming investor conferences to discuss their biopharmaceutical endeavors. The company aims to transform medicines and lives through its innovative approach.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
conferences
-
Rhea-AI Summary
Avadel Pharmaceuticals plc responds to a jury ruling from the United States District Court for the District of Delaware in a patent suit brought by Jazz Pharmaceuticals Inc. regarding LUMRYZ™. The jury ruled in favor of Avadel on one patent but against on another. Avadel plans to vigorously defend its position, including a possible appeal, to overturn the unfavorable ruling. The company remains optimistic about the commercial launch and transformative potential of LUMRYZ™ for narcolepsy patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.57%
Tags
none
Rhea-AI Summary
Avadel Pharmaceuticals plc (AVDL) reported $19.5 million in Q4 and $28.0 million in full-year 2023 net revenue from LUMRYZ sales. Over 2,200 patients enrolled in RYZUPTM with 1,200 starting therapy. Payer coverage exceeds 80% with new listings like United Healthcare and Anthem. FDA set a September 7, 2024, target action date for LUMRYZ's sNDA in pediatric narcolepsy. Financially, R&D expenses decreased due to lower pre-commercial costs, while SG&A expenses rose due to LUMRYZ launch and increased headcount. Net losses slightly increased to $28.8 million for Q4 and $160.3 million for the year. Cash, cash equivalents, and marketable securities stood at $105.1 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.57%
Tags
-
Rhea-AI Summary
Avadel Pharmaceuticals plc (AVDL) schedules conference call to discuss financial results for Q4 and full year 2023, along with a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.93%
Tags
-
Rhea-AI Summary
Avadel Pharmaceuticals plc (AVDL) will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 14. The live webcast and archived recording will be available on Avadel's Investor Relations website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.48%
Tags
conferences
Rhea-AI Summary
Avadel Pharmaceuticals plc (AVDL) Expects $19M in Q4 2023 and $28M in Full Year Net Revenue from LUMRYZ Sales, Receives Positive Feedback for LUMRYZ Launch, and Signs Contract with Emisar (Optum Rx GPO)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.46%
Tags
none
-
Rhea-AI Summary
Avadel Pharmaceuticals plc (Nasdaq: AVDL) reported $7.0 million in LUMRYZ™ net revenue for Q3 from U.S. commercial launch. With over 1,000 patients enrolled in RYZUPTM and 400 patients initiating therapy, LUMRYZ will be added to CVS formularies in 2024. The company also submitted an sNDA for LUMRYZ in pediatric narcolepsy population on November 7th.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.95%
Tags
-
Rhea-AI Summary
Avadel Pharmaceuticals plc (Nasdaq: AVDL) will participate in the Jefferies London Healthcare Conference on November 14 and the Piper Sandler 35th Annual Healthcare Conference on November 29, with live webcasts and archived recordings available on the company's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.35%
Tags
conferences
Rhea-AI Summary
Avadel Pharmaceuticals plc (Nasdaq: AVDL) will host a conference call and webcast on November 8, 2023, to provide a corporate update and discuss the financial results for Q3 2023. The call can be accessed on the company's website and a replay will be available for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.63%
Tags
Avadel Pharmaceuticals plc

Nasdaq:AVDL

AVDL Rankings

AVDL Stock Data

1.64B
66.69M
4.9%
64.09%
11.48%
Medicinal and Botanical Manufacturing
Manufacturing
Link
Ireland
Dublin

About AVDL

avadel pharmaceuticals plc (nasdaq: avdl) is a specialty pharmaceutical company that seeks to develop differentiated pharmaceutical products that are safe, effective and easy to take, helping patients adhere to their prescribed medical treatment and see better results. avadel’s current portfolio of products and product candidates focuses on the urology, central nervous system (cns) / sleep, and hospital markets. the company is headquartered in dublin, ireland with operations in st. louis, missouri and lyon, france.